K5O

Ziftomenib

Created:2023-06-02
Last modified:  2024-11-20

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count91
Chiral Atom Count1
Bond Count96
Aromatic Bond Count20
2D diagram of K5O
Toggle HydrogenToggle Labels

Chemical Component Summary

NameZiftomenib
Systematic Name (OpenEye OEToolkits)4-methyl-5-[[4-[[2-(methylamino)-6-[2,2,2-tris(fluoranyl)ethyl]thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2~{S})-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
FormulaC33 H42 F3 N9 O2 S2
Molecular Weight717.871
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01CS(=O)(=O)N1CCN(CC1)C(C)Cn1c2ccc(CN3CCC(CC3)Nc3nc(nc4sc(cc34)CC(F)(F)F)NC)c(C)c2cc1C#N
SMILESCACTVS3.385CNc1nc(NC2CCN(CC2)Cc3ccc4n(C[CH](C)N5CCN(CC5)[S](C)(=O)=O)c(cc4c3C)C#N)c6cc(CC(F)(F)F)sc6n1
SMILESOpenEye OEToolkits2.0.7Cc1c(ccc2c1cc(n2CC(C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)Nc5c6cc(sc6nc(n5)NC)CC(F)(F)F
Canonical SMILESCACTVS3.385 CNc1nc(NC2CCN(CC2)Cc3ccc4n(C[C@H](C)N5CCN(CC5)[S](C)(=O)=O)c(cc4c3C)C#N)c6cc(CC(F)(F)F)sc6n1
Canonical SMILESOpenEye OEToolkits2.0.7 Cc1c(ccc2c1cc(n2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)Nc5c6cc(sc6nc(n5)NC)CC(F)(F)F
InChIInChI1.06 InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1
InChIKeyInChI1.06 BGGALFIXXQOTPY-NRFANRHFSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB17171 
NameZiftomenib
Groups
  • investigational
  • approved
DescriptionZiftomenib is a potent and highly selective menin inhibitor.[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.[L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.[A274738, L54623]
Synonyms
  • 1h-indole-2-carbonitrile, 4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)-1-piperidinyl)methyl)-1-((2s)-2-(4-(methylsulfonyl)-1-piperazinyl)propyl)-
  • Ziftomenib
  • Menin-mll interaction inhibitor ko 539
  • (s)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1h-indole-2-carbonitrile
  • (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3- d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1Hindole-2-carbonitrile
Brand NamesKomzifti
IndicationZiftomenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.[L54623]
Categories
  • BCRP/ABCG2 Substrates
  • Cytochrome P-450 CYP1A2 Inducers
  • Cytochrome P-450 CYP1A2 Inducers (strength unknown)
  • Cytochrome P-450 CYP3A Substrates
  • Cytochrome P-450 CYP3A4 Substrates
CAS number2134675-36-6

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
MeninMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAV...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknowninducer
UDP-glucuronosyltransferase 1A9MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...unknowninhibitor
UDP-glucuronosyltransferase 2B17MSLKWMSVFLLMQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRG...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 138497449
ChEMBL CHEMBL5095038